Facebook
Twitter
Telegram
Report an ErrorKeros Therapeutics Balance Sheet 2011-2024 | KROS
Annual Balance Sheet Keros Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-317 M | -266 M | -229 M | -265 M | -5.74 M | -22.5 M | - | - | - | - | - | - | - |
Long Term Debt |
13.4 M | 12.8 M | 231 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1 M | 455 K | 862 K | 423 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 538 K | 1.02 M | 3.18 M | - | - | - | - | - | - | - |
Total Current Liabilities |
24.4 M | 16.5 M | 11.8 M | 7.18 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
37.8 M | 29.4 M | 12.1 M | 7.72 M | 5.5 M | 14.7 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 10 M | - | - | - | - | - | - | - |
Retained Earnings |
-381 M | -228 M | -124 M | -65 M | -19.6 M | -7.31 M | - | - | - | - | - | - | - |
Total Assets |
370 M | 307 M | 255 M | 269 M | 11 M | 27.4 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
331 M | 279 M | 230 M | 266 M | 7.14 M | - | - | - | - | - | - | - | - |
Book Value |
332 M | 277 M | 243 M | 262 M | 5.45 M | 12.8 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
332 M | 277 M | 243 M | 262 M | -19.4 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Keros Therapeutics
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
13.2 M | 13.4 M | 13.7 M | 14 M | 14 M | 12.8 M | - | - | - | 231 K | 453 K | 242 K | 361 K | 476 K | 476 K | 476 K | 476 K | 899 K | 899 K | 899 K | 899 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
31.9 M | 37.8 M | 30.4 M | 30 M | 29.5 M | 29.4 M | 11.5 M | - | 11.6 M | 12.1 M | 11.5 M | 7.8 M | 9.36 M | 7.72 M | 7.72 M | 7.72 M | 7.72 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-425 M | -381 M | -341 M | -302 M | -264 M | -228 M | -199 M | - | -148 M | -124 M | -117 M | -96.5 M | -80.9 M | -65 M | -65 M | -65 M | -65 M | -19.6 M | -19.6 M | -19.6 M | -19.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
486 M | 370 M | 326 M | 356 M | 384 M | 307 M | 253 M | - | 235 M | 255 M | 230 M | 243 M | 258 M | 269 M | 269 M | 269 M | 269 M | 11 M | 11 M | 11 M | 11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
442 M | 331 M | 288 M | 322 M | 351 M | 279 M | 239 M | 216 M | 229 M | 230 M | 221 M | 237 M | 255 M | 266 M | 266 M | 266 M | 266 M | 7.02 M | 7.02 M | 7.02 M | 7.02 M | 23.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
454 M | 332 M | 296 M | 326 M | 355 M | 277 M | 241 M | - | 223 M | 243 M | 218 M | 236 M | 248 M | 262 M | 262 M | 262 M | 262 M | 495 K | 495 K | 495 K | 495 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
454 M | 332 M | 296 M | 326 M | 355 M | 277 M | 241 M | 211 M | 223 M | 243 M | 218 M | 236 M | 248 M | 262 M | 262 M | 262 M | 262 M | -19.4 M | -19.4 M | -19.4 M | -19.4 M | -7.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency